Description du projet
Innovations dans la compréhension et la prévention de l’obésité infantile
L’obésité à la fin de l’adolescence peut avoir des effets néfastes à long terme, contribuant à l’obésité sévère, au diabète, aux maladies cardiovasculaires, à la mort prématurée et au handicap. Cependant, le traitement de l’obésité chez les jeunes peut avoir des résultats positifs. Compte tenu de l’augmentation des taux d’obésité chez les enfants en Europe, il est essentiel de donner la priorité à des stratégies de prévention et de traitement efficaces. Le projet OBELISK, financé par l’UE, entend faire la lumière sur les causes de l’obésité et fournir une médecine de précision aux enfants atteints d’obésité. Il introduira des innovations dans la compréhension des mécanismes moléculaires qui sous-tendent l’interaction des facteurs causaux favorisant ou prévenant la transition vers l’obésité pendant l’enfance. L’équipe développera également des outils de prédiction précoce. OBELISK collaborera avec les familles, les communautés scientifiques et médicales, les écoles, les municipalités et les industries.
Objectif
Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success.
OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities.
OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.
Champ scientifique
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencespersonalized medicine
- medical and health scienceshealth sciencesnutritionobesity
Mots‑clés
Programme(s)
Thème(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
75654 Paris
France